Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Acitretin
Drug ID BADD_D00036
Description An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
Indications and Usage For the treatment of severe psoriasis in adults.
Marketing Status approved
ATC Code D05BB02
DrugBank ID DB00459
KEGG ID D02754
MeSH ID D017255
PubChem ID 5284513
TTD Drug ID D05QDC
NDC Product Code 17337-0003; 59981-011; 0093-1136; 0115-1752; 42291-087; 62147-0145; 0115-1751; 42794-081; 0378-7020; 71214-0698; 42291-088; 58159-058; 71052-692; 0115-1753; 17337-0004; 71214-0667; 0115-1750; 71214-0668; 71214-0669; 42291-086; 42794-080; 0093-1135; 0093-1138; 62147-0146; 76055-0001; 42794-083; 0378-7023
UNII LCH760E9T7
Synonyms Acitretin | Etretin | Isoacitretin | Isoetretin | Ro 10-1670 | Ro 101670 | Ro-10-1670 | Ro101670 | 13-cis-Acitretin | Neotigason | Soriatane | Acitretin, (Z,E,E,E)-Isomer | Ro-13-7652 | Ro137652 | Ro 13-7652 | Ro 137652
Chemical Information
Molecular Formula C21H26O3
CAS Registry Number 55079-83-9
SMILES CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thirst14.03.02.007; 08.01.09.021--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue disorder07.14.01.002--Not Available
Tongue ulceration07.14.01.003--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urine abnormality20.02.01.013--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vaginal discharge21.08.02.002--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vasculitis24.12.04.027; 10.02.02.006--
Vision blurred17.17.01.010; 06.02.06.0070.001250%
Visual acuity reduced17.17.01.011; 06.02.10.012--
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Visual impairment06.02.10.0130.001250%Not Available
Vitamin D deficiency14.12.03.0030.001250%Not Available
VIth nerve paralysis17.04.02.002; 06.05.02.0090.001875%Not Available
Vomiting07.01.07.003--
Vulvovaginitis21.14.02.005; 11.01.10.003--Not Available
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
White blood cell count decreased13.01.06.012--
White blood cell count increased13.01.06.013--Not Available
White blood cells urine positive13.13.02.004--Not Available
Xerophthalmia14.12.03.002; 06.06.03.008--Not Available
Xerosis08.01.03.016--Not Available
Vasculitis gastrointestinal24.12.04.028; 10.02.02.022; 07.08.03.0130.001250%Not Available
Joint range of motion decreased15.01.02.0060.001875%
Onychoclasis23.02.05.005--Not Available
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Osteopenia14.04.04.004; 15.02.03.0030.001875%Not Available
The 11th Page    First    Pre   11 12 13 14    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene